Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  selumetinib
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00065, NCI-2013-01983, EudraCT 2013-000423-14, NCT01843062
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00079, NCI-2014-00422, 2013-001676-38, NCT01933932
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029B, NCI-2012-03173, CDR667932, PBTC-029, NCT01089101
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
Targeted Enzyme Inhibitor Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, 8639, NCT01306045
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00064, NCI-2013-00085, 2012-003622-25, EudraCT number: 2012-003622-25, NCT01750281
Selumetinib in Treating Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9840, NCI-2015-00456, NCT02407405
Selumetinib in Treating Younger Patients with Neurofibromatosis Type 1 or Plexiform Neurofibromas That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 18
Trial IDs: 11-C-0161, NCI-2013-01491, 110161, 748727, P11809, 8799, NCT01362803
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00006, NCI-2014-02005, NCT02143466
Selumetinib and Cyclosporine in Treating Patients with Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2628, NCI-2014-01484, P9571_A01PAMDREVW01, 9571, NCT02188264
Start Over